Gentian Diagnostics AS serves the global market with sensitive diagnostic tests. Current and pipeline products contribute to improved diagnostics and cost reductions in treatment of kidneys, inflammation, cardiovascular diseases, cancer and viral infections.
On 14th December, 2016, Gentian Diagnostics AS was admitted to the Oslo Stock Exchange list ‘Merkur Market’ under GENT-ME.
Find more information about the Gentian Share on Oslo Børs.
Learn more about Gentian Diagnostics AS here.
9TH MAY – ANNUAL REPORT
9TH MAY – QUARTERLY REPORT Q1
28TH MAY – ANNUAL GENERAL MEETING
15TH AUG – HALF–YEARLY REPORT
7TH NOV – QUARTERLY REPORT – Q3
The Extraordinary General Meeting for Gentian Diagnostics AS was hold on the 21st of November 2019.
For more information, please see the documents below
Annual General Meeting for Gentian Diagnostics AS was hold on the 28th of May 2019. For more information, please see the notice and documents below: